Drug Information

Drug (ID: DG00478) and It's Reported Resistant Information

• Name: Anti-EGFR treatment
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
  COVID-19 [ICD-11: 1D92]; [1]
  Lung cancer [ICD-11: 2C25]; [2]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Epidermal growth factor receptor (EGFR) [2]

• Molecule Alteration: Missense mutation; p.T790M
• Resistant Disease: Non-small cell lung cancer [ICD-11: 2C25.Y]
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: A retrospective survey in conducting clinical studies; Homo sapiens
• Experiment for Molecule Alteration: Longitudinal quantitative cfDNA analysis
• Experiment for Drug Resistance: Plasma-based tumor genotyping assay
• Mechanism Description: In patients with non-small cell lung cancer, the use of first-line anti-EGFR treatment in patients with activating EGFR mutations often leads to secondary resistance through an additional T790M mutation in EGFR in ~50% of initial responders.

References

• Ref 1: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
• Ref 2: Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther. 2017 Jun;174:22-26. doi: 10.1016/j.pharmthera.2017.02.003. Epub 2017 Feb 3.